0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a Phase 3 study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The interleukin (IL)-23/IL-17 axis has been shown critical in the pathogenesis of psoriasis.

          Related collections

          Author and article information

          Journal
          Br. J. Dermatol.
          The British journal of dermatology
          Wiley-Blackwell
          1365-2133
          0007-0963
          May 19 2017
          Affiliations
          [1 ] Dermatologikum Hamburg, Hamburg, Germany and Georg-August-University, Göttingen, Germany.
          [2 ] Department of Dermatology, Venereology, and Allergology, Universitiy Clinic Frankfurt, Frankfurt am Main, Germany.
          [3 ] Department of Dermatology, University Hospital of Nice, Nice, France.
          [4 ] Servicio de Dermatología, Hospital Universitario Germans Trias i Pujol, Universitat Autónoma de Barcelona, Badalona, Barcelona, Spain.
          [5 ] Dermatology Clinic, University of Catania, University Hospital Policlinico-Vittorio Emanuele, Catania, Sicily, Italy.
          [6 ] Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland.
          [7 ] DermEdge Research, Mississauga, Ontario, Canada.
          [8 ] Eli Lilly and Company, Indianapolis, IN, USA.
          [9 ] Dermatology Department, CHU, Paul Sabatier University, Toulouse, France.
          Article
          10.1111/bjd.15666
          28542874

          PASI 90, clinical trial, ixekizumab, psoriasis, ustekinumab

          Comments

          Comment on this article